Provide for insurance and medicaid coverage of biomarker testing

Nebraska's LB 253 requires health insurers and Medicaid to cover biomarker testing for diagnosis, treatment, or monitoring of diseases when supported by medical evidence. This includes tests approved by the FDA, aligned with drug labels, or recommended by nationally recognized clinical guidelines. Insurers must cover these tests without unnecessary delays, approving or denying prior authorization requests within 24-72 hours, and provide clear exception processes for patients. The law applies to all health insurers and Medicaid plans in Nebraska, effective January 1, 2026, directly affecting patients needing these tests and healthcare providers ordering them.